iNK-CD64/16A cells: a promising approach for ADCC?

Research output: Contribution to journalEditorialpeer-review

2 Scopus citations

Abstract

Introduction: ADCC by natural killer (NK) cells is a key mechanism for several clinically successful tumor-targeting therapeutic antibodies. Most patients, however, have limited responses to this therapy and/or develop resistance. NK cells exclusively recognize IgG by their low-affinity FcγR CD16A. Areas covered: We describe in this editorial a novel recombinant FcγR that consists of CD64, the only high affinity IgG receptor, and the transmembrane and cytoplasmic regions of CD16A, a potent activating receptor. CD64/16A was expressed in engineered iPSCs that were differentiated into NK cells (referred to as iNK cells). Expert opinion: iNK-CD64/16A cells in combination with therapeutic antibodies provide a universal tumor antigen targeting approach and potential off-the-shelf cell therapy to treat various malignancies.

Original languageEnglish (US)
Pages (from-to)1229-1232
Number of pages4
JournalExpert opinion on biological therapy
Volume19
Issue number12
DOIs
StatePublished - Dec 2 2019

Bibliographical note

Funding Information:
This paper was funded by the National Institutes of Health, including R01CA203348 and R21AI125729, and the Minnesota Ovarian Cancer Alliance.

Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.

Keywords

  • Fc receptor
  • Natural killer cells
  • antibody
  • cancer
  • cell therapy
  • mAb therapy
  • stem cell

Fingerprint Dive into the research topics of 'iNK-CD64/16A cells: a promising approach for ADCC?'. Together they form a unique fingerprint.

Cite this